公开(公告)号：US12286445B2

公开(公告)日：2025-04-29

申请号：US17960092

申请日：2022-10-04

Applicant: UNIVERSITY OF SOUTH FLORIDA

Inventor： Michael John Zaworotko ,  Naga Duggirala ,  Adam John Smith ,  Roland Douglas Shytle

IPC: C07F1/02 ,  A61K33/00 ,  A61K33/14 ,  A61K45/06 ,  C07C229/08 ,  C07D207/16

Abstract: A cocrystal having the formula LiX·aM, or a solvate or hydrate thereof, wherein X is a conjugate base of an organic acid, M is a neutral organic molecule, and a is from 0.5 to 4, pharmaceutical compositions comprising such cocrystals, cocrystal solvates, or cocrystal hydrates, and methods of preparing such cocrystals, cocrystal solvates, or cocrystal hydrates, and such pharmaceutical compositions.

公开(公告)号：US11459341B1

公开(公告)日：2022-10-04

申请号：US17119270

申请日：2020-12-11

Applicant: UNIVERSITY OF SOUTH FLORIDA

Inventor： Michael John Zaworotko ,  Naga Duggirala ,  Adam John Smith ,  Roland Douglas Shytle

IPC: C07F1/02 ,  A61K33/00 ,  C07C229/00 ,  A61K45/06 ,  C07D207/16 ,  A61K33/14 ,  C07C229/08

Abstract: A cocrystal having the formula LiX.aM, or a solvate or hydrate thereof, wherein X is a conjugate base of an organic acid, M is a neutral organic molecule, and a is from 0.5 to 4, pharmaceutical compositions comprising such cocrystals, cocrystal solvates, or cocrystal hydrates, and methods of preparing such cocrystals, cocrystal solvates, or cocrystal hydrates, and such pharmaceutical compositions.

公开(公告)号：US10435416B2

公开(公告)日：2019-10-08

申请号：US15793435

申请日：2017-10-25

Applicant: University of South Florida

Inventor： Michael John Zaworotko ,  Naga Duggirala ,  Adam John Smith ,  Roland Douglas Shytle

IPC: C07F1/02 ,  A61K33/00 ,  A61K33/14 ,  A61K45/06 ,  C07C229/08 ,  C07D207/16

Abstract: A cocrystal having the formula LiX.aM, or a solvate or hydrate thereof, wherein X is a conjugate base of an organic acid, M is a neutral organic molecule, and a is from 0.5 to 4, pharmaceutical compositions comprising such cocrystals, cocrystal solvates, or cocrystal hydrates, and methods of preparing such cocrystals, cocrystal solvates, or cocrystal hydrates, and such pharmaceutical compositions.

公开(公告)号：US09840521B2

公开(公告)日：2017-12-12

申请号：US14779774

申请日：2014-04-18

Applicant: University of South Florida

Inventor： Michael John Zaworotko ,  Naga Duggirala ,  Adam John Smith ,  Roland Douglas Shytle

IPC: A61K33/00 ,  A61K33/14 ,  A61K45/06 ,  C07C229/08 ,  C07D207/16 ,  C07F1/02

CPC classification number: C07F1/02 ,  A61K33/00 ,  A61K33/14 ,  A61K45/06 ,  C07C229/08 ,  C07D207/16

Abstract: A cocrystal having the formula LiX.aM, or a solvate or hydrate thereof, wherein X is a conjugate base of an organic acid, M is a neutral organic molecule, and a is from 0.5 to 4, pharmaceutical compositions comprising such cocrystals, cocrystal solvates, or cocrystal hydrates, and methods of preparing such cocrystals, cocrystal solvates, or cocrystal hydrates, and such pharmaceutical compositions.

公开(公告)号：US09662351B2

公开(公告)日：2017-05-30

申请号：US14644109

申请日：2015-03-10

Applicant: University of South Florida

Inventor： Adam John Smith ,  R. Douglas Shytle

IPC: A61K33/00 ,  A61K31/60 ,  A61K31/00

CPC classification number: A61K33/00 ,  A61K31/00 ,  A61K31/60

Abstract: Despite its narrow therapeutic window, lithium is regarded as the gold standard comparator and benchmark treatment for mania. Attempts to find new drugs with similar therapeutic activities have yielded new chemical entities. However, these new drugs have yet to match the many bioactivities attributable to lithium's efficacy for the treatment of neuropsychiatric diseases. Consequently, an intense effort for re-engineering lithium therapeutics using crystal engineering is underway. The evaluation of pharmacokinetics of previously unexplored lithium salts with organic anions (i.e. lithium salicylate) has found that these lithium salts exhibit profoundly different pharmacokinetics compared to the more common FDA approved salt, lithium carbonate, in rats. Remarkably, lithium salicylate produced elevated blood and brain levels of lithium beyond 48 hours post-dose without the sharp peak that contributes to the toxicity problems of current lithium therapeutics.